Verastem Stock Price, News & Analysis

Verastem Oncology (Nasdaq: VSTM) announced that its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 10:25 AM ET in Miami, Florida.

A live webcast will be available under “Events & Presentations” on the company website at www.verastem.com, and a replay will be archived on the site for approximately 90 days following the presentation.

Verastem Oncology (Nasdaq: VSTM) priced an underwritten public offering to raise approximately $90 million gross. The company will sell 8,543,794 common shares at $7.25 per share and, in lieu of common stock to certain investors, 3,870,000 pre-funded warrants at $7.2499 each (with a $0.0001 exercise price).

The underwriters have a 30-day option for up to 1,862,069 additional common shares. The offering is expected to close on or about November 17, 2025. Net proceeds are intended to fund commercial activities for AVMAPKI FAKZYNJA co-pack (FDA approved for KRAS-mutated recurrent low-grade serous ovarian cancer), continued R&D including the VS-7375 KRAS G12D program, and general corporate purposes.

Verastem Oncology (Nasdaq: VSTM) announced a proposed underwritten public offering of its common stock, with underwriters granted a 30-day option to buy up to an additional 15% of shares. The offering is subject to market conditions and may not be completed.

Verastem said it will use net proceeds to fund commercial activities for the FDA-approved AVMAPKI FAKZYNJA co-pack for KRAS-mutated recurrent low-grade serous ovarian cancer, continue clinical R&D including the VS-7375 KRAS G12D program, and for working capital. A Form S-3 shelf was declared effective on Nov 20, 2023.

Verastem Oncology (Nasdaq: VSTM) said its management team will present at two investor conferences in November 2025: a Guggenheim Healthcare Conference fireside chat on Tuesday, November 11 at 1:00 pm ET, and a Jefferies Global Healthcare Conference fireside chat in London on Wednesday, November 19 at 2:30 pm GMT (9:30 am ET).

A live webcast of both fireside chats will be available under Events & Presentations on the company investor website and replays will be archived for approximately 90 days after each presentation.

Verastem Oncology (Nasdaq: VSTM) reported Q3 2025 results and business updates on November 4, 2025. Key commercial and clinical highlights include $11.2M net product revenue in the first full quarter post-launch of AVMAPKI FAKZYNJA CO-PACK, completion of planned enrollment for the Phase 3 RAMP 301 trial (270 patients) with an IDMC-recommended one-time +29 patient increase, and VS-7375 clearing 400 mg and 600 mg monotherapy doses with no dose-limiting toxicities.

Financials: total operating expenses $52.0M, GAAP net loss $98.5M (loss per share $1.35), non-GAAP adjusted net loss $39.4M, and cash, cash equivalents and investments of $137.7M, with runway into H2 2026 assuming product revenue and warrant exercises.

Verastem Oncology (Nasdaq: VSTM) reported encouraging preliminary Phase 1/2a data for oral KRAS G12D inhibitor VS-7375. The 400 mg QD and 600 mg QD monotherapy dose levels cleared with no dose-limiting toxicities observed and no nausea, vomiting, or diarrhea > Grade 1 at those doses. Of five efficacy-evaluable patients with at least one scan, 4 of 5 showed tumor reduction and remain on treatment. The study has opened a dose-escalation cohort at 900 mg QD and initiated enrollment of a combination cohort of VS-7375 with cetuximab including colorectal cancer patients. An interim safety and efficacy update is planned for first half of 2026.

Verastem Oncology (Nasdaq: VSTM) will report third quarter 2025 financial results and business updates on Tuesday, November 4, 2025 at 8:00 AM ET. The company will host a conference call and live audio webcast with accompanying slides available in the Investor "Events & Presentations" section at https://investor.verastem.com/events.

Dial-in details: (888) 596-4144 (U.S.) or (646) 968-2525 (international); enter passcode 8194537 at least 10 minutes before the call. A replay of the webcast will be archived and available after the event.

Verastem Oncology (Nasdaq: VSTM) reported updated data from partner GenFleet’s Phase 1/2 monotherapy study of GFH375 (VS-7375 outside China) in advanced KRAS G12D mutant pancreatic ductal adenocarcinoma, presented at ESMO 2025 on October 19, 2025. At the 600 mg daily RP2D, 59 efficacy-evaluable patients showed an ORR of 40.7% (24/59) and a DCR of 96.7% (57/59). Median PFS was 5.52 months (median follow-up 5.65 months); 4-month OS was 92.2% and median OS was not reached. Safety: Grade 3 TRAEs in 30.3%, Grade 4 in 1.5%, dose reductions in 6.1%, discontinuations for TRAEs 3%, and mean relative dose intensity 93%.

Verastem Oncology (Nasdaq: VSTM) granted inducement stock options to nine new employees to purchase 138,000 shares of common stock under Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $8.80 per share (closing price on October 1, 2025). 118,000 options vest 25% after one year, then quarterly over three years, subject to continued service. 20,000 options for one employee vest upon specified business development milestones, subject to continued service.